This chapter explores the role of weight-loss drugs in preventing obesity-related health issues and their popularity among celebrities. It discusses the criticisms and concerns surrounding these drugs, including supply constraints and unequal access, and raises questions about equal availability and the pharmaceutical industry.
Chancellor Jeremy Hunt raised the prospect of the Bank of England reducing interest rates in 2024 in an interview with the FT, and Novo Nordisk’s drugs for obesity could have a profound effect on healthcare, society and our relationship with food. Plus, part three or our three-part series on a changing India looks at the country’s booming fertility industry.
Mentioned in this podcast:
FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk
Jeremy Hunt raises prospect of Bank of England rate cuts in 2024
Credit: Vogue.com
Credit: Jimmy Kimmel Live
The FT News Briefing is produced by Fiona Symon, Sonja Hutson, Kasia Broussalian and Marc Filippino. Additional help by Breen Turner, Peter Barber, Michael Lello, David da Silva and Gavin Kallmann. Our engineer is Monica Lopez. Topher Forhecz is the FT’s executive producer. The FT’s global head of audio is Cheryl Brumley. The show’s theme song is by Metaphor Music.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.